

Marc André Rodwin
Publications since 2013

2023

Lantos, J, and Rodwin, M.A. The FDA's Dueling Narratives: Protector Versus Obstacle. *Health Affairs Forefront*, Aug. 29, 2023. [click here](#)

2022

Rodwin, M.A. and Sager, A., 2022. The No Surprises Act: Conservative Band-Aid to Protect business as usual. *STAT* first opinion. [click here](#)

Rodwin, M.A. and Sager, A., 2022. The No Surprises Act: A Conservative Band-Aid to Protect Business as Usual. *International Journal of Social Determinants of Health and Health Services*, 53(1), pp.63-68. [click here](#)

Rodwin, M.A., 2022. Assessing US Pharmaceutical Policy and Pricing Reform Legislation in Light of European Price and Cost Control Strategies. *Journal of Health Politics, Policy and Law*, 47(6), pp.755-778. [click here](#)

Rodwin, M.A. and Gerke, S., 2022. German Pharmaceutical pricing: lessons for the United States. *International Journal of Health Services*, 52(1), pp.146-158. [click here](#)

Rodwin, M.A., 2022. WHO's Attempt to Navigate Commercial Influence and Conflicts of Interest in Nutrition Programs While Engaging With Non-State Actors: Reflections on WHO Guidance for Nation States Comment on "Towards Preventing and Managing Conflict of Interest in Nutrition Policy? An Analysis of Submissions to a Consultation on a Draft WHO Tool". *International Journal of Health Policy and Management*, 11(3), pp.386-390. [click here](#)

2021

Rodwin, M.A., 2021. Common pharmaceutical price and cost controls in the United Kingdom, France, and Germany: lessons for the United States. *International Journal of Health Services*, 51(3), pp.379-391. [click here](#)

Rodwin, M.A., 2021. How the United Kingdom controls pharmaceutical prices and spending: learning from its experience. *International Journal of Health Services*, 51(2), pp.229-237. [click here](#)

Rodwin, M.A., Mancini, J., Duran, S., Jalbert, A.C., Viens, P., Maraninchi, D., Gonçalves, A. and Marino, P., 2021. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004–2017. *European Journal of Cancer*, 145, pp.11-18. [click here](#)

Rodwin, M.A., 2021. Conflicts of interest in medical practice: Causes and cures. In, Hauray, B., Boullier, H., Gaudillière, J.P. and Michel, H., 2021. Conflict of interest and medicine. Knowledge, practices, and mobilizations, London, Routledge. (pp. 109-128). [click here](#)

2020

Rodwin, M.A., 2020. Pharmaceutical price and spending controls in France: lessons for the United States. *International Journal of Health Services*, 50(2), pp.156-165. [click here](#)

Rodwin, M.A., 2020. Average international market pricing for us pharmaceuticals—lessons from Europe. *Health Affairs Forefront*. [10.1377/forefront.20200917.35750](https://doi.org/10.1377/forefront.20200917.35750) [click here](#)

Rodwin, Marc A. Conflicts of interest in Human Subject Research: Best Practices, International Standards, and Challenges in Implementing US regulations. In, Ulf Schmidt, Andreas Frewer, and Dominique Sprumont eds.) in *Human Research Ethics And The Declaration Of Helsinki* (Oxford University Press) (2020) pp 311-350. [click here](#)

2019

Rodwin, M.A., 2019. Conflicts of interest in human subject research: the insufficiency of US and international standards. *American Journal of Law & Medicine*, 45(4), pp.303-330. [click here](#)

Moynihan, R., Bero, L., Hill, S., Johansson, M., Lexchin, J., Macdonald, H., Mintzes, B., Pearson, C., Rodwin, M.A., Stavdal, A. and Stegenga, J., 2019. Pathways to independence: towards producing and using trustworthy evidence. *Bmj*, 367, pp. 1-5. [click here](#)

Rodwin, M.A., 2019. What can the United States learn from pharmaceutical spending controls in France?. *Commonwealth Fund Issue Brief*, November, pp.1-7. [click here](#)

Rodwin, M.A., 2019. Conflict of interest in the pharmaceutical sector: a guide for public management. *DePaul J. Health Care L.*, 21, p.1-34. [click here](#)

Rodwin, M.A., 2019. Price Discrimination Rather Than Lack of Transparency Explains Retail Pharmacy Price Variations. *Health and Healthcare in the United States* Edited by Holly Fernandez Lynch, I. Glenn Cohen, Carmel Shachar and Barbara J. Evans. Cambridge University Press, Cambridge, pp.19-11 [click here](#)

Tanaka, Leo, David Pleyne & Marc A. Rodwin. 2018. [The Legal Origins of the New England Compounding Center Crisis](#). *Quinnipiac Health Law Journal*. 21:1-56. [click here](#)

Wiersma, M., Kerridge, I., Lipworth, W. and Rodwin, M., 2018. Should we try to manage non-financial interests?. *BMJ*, 361, doi: <https://doi.org/10.1136/bmj.k1240>. [click here](#)

Rodwin, M.A., 2018. Attempts to redefine conflicts of interest. *Accountability in Research*, 25(2), pp.67-78. [click here](#)

Rodwin, M.A., 2018. Conflicts of interest in medicine: should we contract, conserve, or expand the traditional definition and scope of regulation. *J. Health Care L. & Pol'y*, 21(2), pp.158-188. [click here](#)

2017

Rodwin, M.A., 2017. "Introduction," in Lynch, H. F., Cohen, I.G., and Sepper, E. (eds) *Law, Religion, and Health in the United States*. Cambridge: Cambridge University Press, pp. 139-142. [click here](#)

2016

Robertson, C.T. and Rodwin, M.A., 2016. "Money Blinding" as a Solution to Biased Design and Conduct of Scientific Research. In, Robertson, C.G. and Kesselheim, A. eds., 2016. *Blinding as a solution to bias: Strengthening biomedical science, forensic science, and law*. Academic Press. pp.1-20. [click here](#)

2015

Rodwin, M.A., 2015. Do we need stronger sanctions to ensure legal compliance by pharmaceutical firms. *Food & Drug LJ*, 70(3), p.435-452. [click here](#)

Rodwin, M.A., 2015. Independent drug testing to ensure drug safety and efficacy. *J. Health Care L. & Pol'y*, 18(1), p.43-81. [click here](#)

Rodwin, M.A., Silverman, J. and Merfield, D., 2015. Why the medical malpractice crisis persists even when malpractice insurance premiums fall. *Health Matrix*, 25(1), pp.163-226. [click here](#)

2014

Rodwin, M.A., 2014. Compensating Pharmaceutical Injuries in the Absence of Fault. *Food and Drug Law Journal*, 69(3), pp.447-472. [click here](#)

2013

Rodwin, Marc A. 2013. "Introduction: Institutional Corruption and The Pharmaceutical Policy." *The Journal of Law, Medicine & Ethics*, 41(3): 544-552. [click here](#)

Rodwin, M.A., 2013. Five un-easy pieces of pharmaceutical policy reform. *Journal of Law, Medicine & Ethics*, 41(3), pp.581-589. [click here](#)

Rodwin, M.A., 2013. Institutional corruption and the pharmaceutical policy. *Journal of Law, Medicine & Ethics*, 41(3), pp.544-552. [click here](#)

Maisonneuve, Hervé and Marc A. Rodwin. 2013. "Conflict of Interest In Biomedical Publications." In, Smart, Pippa, Hervé Maisonneuve and Arjan Polderman. *Science Editors' Handbook* (2nd ed.) European Association of Science Editors: 160-63. [click here](#)

Rodwin, M.A., 2013. Rooting out institutional corruption to manage inappropriate off-label drug use. [click here](#)